Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Natural killer cell stress-induced ligands (NKG2DLs) are a group of cell surface proteins, including MHC class I polypeptide-related sequence A (MICA), MICB, and the UL16-binding protein (ULBP) family, that are upregulated on host cells in response to cellular stress, DNA damage, or malignant transformation (PMID: 21739672). These ligands serve as critical recognition signals for the immune system by binding to the activating receptor NKG2D (KLRK1) expressed on Natural Killer (NK) cells and certain T cell subsets (UniProt: P43481, Q29980). Binding triggers the activation of effector cells, leading to the targeted destruction of the stressed or transformed host cell through the release of cytotoxic granules (PMID: 11777960). In many cancers, tumors utilize proteolytic shedding of these ligands (e.g., sMICA) as an immune evasion mechanism to desensitize effector cells and avoid detection (PMID: 12191486). Therapeutic strategies currently in development include NKG2D-based CAR-T cells (e.g., CYAD-01), monoclonal antibodies that stabilize ligand expression or prevent shedding (e.g., 7C6), and bispecific engagers designed to bridge NKG2DL-expressing cells with immune effectors (PMID: 29590616, PMID: 31110293).
Binding to the activating NKG2D receptor on effector lymphocytes to trigger cytotoxic granule release and cytokine production against ligand-expressing cells (PMID: 11777960).
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Natural killer cell stress-induced ligands (NKG2DL) (NKG2DL).